• CENTRE FOR COMMERCIALIZATION OF CANCER IMMUNOTHERAPY - C3I

C3i

ACCELERATING MARKET ACCESS OF BREAKTHROUGH
INNOVATIONS TO FIGHT CANCER

News

IRICoR and C3i Announce Partnership to Identify novel Tumor-Specific Antigens (TSAs)

Novel Approach to Identifying TSAs based on a unique mass spectrometry approach discovered at IRIC combined with expertise in genomic sequencing and clinical validation from C3i
MORE